The global targeted RNA sequencing market size is likely to be valued at US$5.2 billion in 2026 and is projected to reach US$9.8 billion by 2033, growing at a CAGR of 9.5% during the forecast period from 2026 to 2033, driven by the growing adoption of RNA sequencing, next-generation sequencing (NGS), and precision medicine in clinical diagnostics and biomedical research.

Advances in sequencing chemistry, bioinformatics, and government-supported genomics initiatives are further strengthening laboratory capabilities and expanding the adoption of gene expression analysis across research and clinical settings.

Driver - Growing Adoption of Precision Medicine and Oncology Research

The expanding adoption of precision medicine is a key driver of the Targeted RNA Sequencing Market. According to the World Health Organization (WHO), around 20 million new cancer cases were diagnosed globally in 2022, increasing demand for advanced molecular profiling to support personalized treatment. The U.S. National Institutes of Health (NIH) continues to invest in large-scale genomics initiatives that integrate sequencing into clinical research. Targeted RNA sequencing enables sensitive gene expression analysis, fusion transcript detection, and biomarker discovery, making it an increasingly important tool in drug development, companion diagnostics, and translational research.

Restraint - High Implementation Costs and Analytical Complexity

High capital investments in sequencing platforms, automated library preparation systems, computational infrastructure, and bioinformatics expertise continue to restrain broader market adoption. Clinical laboratories must also meet stringent validation and quality requirements established by regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) before implementing sequencing-based assays. The complexity of analyzing large transcriptomic datasets and limited reimbursement for advanced genomic testing in several healthcare systems also remain significant barriers, particularly for smaller hospitals and diagnostic laboratories.

Opportunity - Expansion of Multi-omics and Companion Diagnostics

The integration of transcriptomics, genomics, proteomics, and artificial intelligence is creating significant opportunities for the targeted RNA sequencing market. According to the National Human Genome Research Institute (NHGRI), multi-omics is becoming essential for understanding complex diseases and enabling personalized therapies. Growing demand for companion diagnostics, RNA-based therapeutics, and precision drug development is increasing the adoption of targeted sequencing assays, while advances in automation, cloud-based bioinformatics, and single-cell sequencing continue to expand applications across oncology, immunology, and rare disease research.

Sequencing Type Insights

Qualitative targeted RNA sequencing is estimated to account for 58% of the targeted RNA sequencing market in 2026, owing to its widespread use in fusion gene detection, transcript identification, mutation confirmation, and biomarker validation. Its high analytical accuracy and broad application across oncology, infectious disease, and rare disease research continue to support its market leadership.

Meanwhile, quantitative targeted RNA sequencing is expected to register the fastest growth through 2033, driven by increasing demand for precise gene expression analysis, companion diagnostics, therapeutic response monitoring, and precision drug discovery. Advances in sequencing sensitivity, digital quantification technologies, and bioinformatics platforms are further accelerating adoption across research and clinical laboratories.

End-user Insights

Biotechnology companies are anticipated to account for 34% of the market in 2026, supported by increasing investments in RNA sequencing, biomarker discovery, and therapeutic development. Targeted RNA sequencing has become an essential tool for preclinical research, clinical trial biomarker analysis, and companion diagnostic development, while strategic collaborations with sequencing technology providers continue to strengthen adoption.

Clinical research institutes are projected to witness the fastest growth during the forecast period, driven by expanding multicenter genomic studies, government-funded translational research, and growing integration of next-generation sequencing (NGS) into precision oncology and personalized medicine initiatives. This version maintains a professional market research tone while avoiding unnecessary repetition.

North America Targeted RNA Sequencing Market Trends

North America is estimated to account for 41% of the global targeted RNA sequencing market in 2026 and is expected to maintain its leading position through 2033, with the U.S. remaining the primary revenue contributor. The country's advanced genomic research infrastructure, high healthcare expenditure, and widespread adoption of precision medicine are expected to support market growth.

Government initiatives led by the National Institutes of Health (NIH) and the Cancer Moonshot program are anticipated to continue expanding genomics research and translational medicine. Favorable regulatory pathways, established reimbursement mechanisms for molecular diagnostics, and the presence of major sequencing technology providers are further expected to reinforce North America's market leadership.

Europe Targeted RNA Sequencing Market Trends

Europe is expected to remain a significant market, with Germany leading, owing to its strong biotechnology industry, advanced research infrastructure, and sustained investments in genomics and molecular diagnostics. The U.K., France, and Spain are also anticipated to contribute to regional growth through expanding precision medicine initiatives and collaborative genomic research programs.

Implementation of the In Vitro Diagnostic Regulation (IVDR) is expected to improve quality standards for molecular diagnostics and encourage wider adoption of validated RNA sequencing workflows. Continued public and private investments are likely to strengthen Europe's innovation ecosystem throughout the forecast period.

Asia Pacific Targeted RNA Sequencing Market Trends

Asia Pacific is estimated to register the fastest growth during the forecast period, expanding at an estimated CAGR of 11.4% from 2026 to 2033. China is expected to remain the leading country within the region, supported by substantial investments in genomics infrastructure, biotechnology innovation, and precision medicine programs.

Japan is anticipated to maintain steady demand through advanced clinical genomics capabilities, while India and Southeast Asian countries are expected to witness increasing adoption driven by improving healthcare infrastructure, expanding molecular diagnostics capacity, and growing pharmaceutical research activities. These factors are likely to position Asia Pacific as the fastest-growing regional market for targeted RNA sequencing over the forecast period.

The global targeted RNA sequencing market is moderately consolidated, with leading players such as Illumina, Thermo Fisher Scientific, Roche, QIAGEN, and Pacific Biosciences competing through advanced sequencing platforms, integrated workflows, and bioinformatics solutions. Competition is increasingly focused on sequencing accuracy, automation, turnaround time, and multi-omics capabilities. Strategic collaborations with pharmaceutical companies, research institutes, and clinical laboratories continue to strengthen market positioning and support expansion in precision medicine and clinical genomics.

Key Industry Developments:

• In February 2025, Roche launched its Sequencing by Expansion (SBX) platform to enable faster, scalable RNA sequencing, whole-genome sequencing, and multi-omics research.
• In February 2025, Illumina partnered with Broad Clinical Labs to accelerate large-scale single-cell sequencing workflows for drug discovery and precision medicine.